Acute Coronary Syndromes in Patients with Hematological Disorders

1. Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med. 2003;3:147-182. doi: 10.1055/s-2003-40673.10.1055/s-2003-4067315199478Search in Google Scholar

2. Balasubramaniyam N, Kolte D, Palaniswamy C, et al. Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura. Am J Med. 2013;126:1016.e1-7. doi: 10.1016/j.amjmed.2013.03.021.10.1016/j.amjmed.2013.03.02123993262Search in Google Scholar

3. Gandhi K, Aronow WS, Desai H, et al. Cardiovascular Manifestations in Patients With Thrombotic Thrombocytopenic Purpura: A Single-center Experience. Clin Cardiol. 2010 Apr;33(4):213-6. doi: 10.1002/clc.20731.10.1002/clc.20731665300020394041Search in Google Scholar

4. Wahla AS, Ruiz J, Noureddine N, Upadhya B, Sane DC, Owen J. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol. 2008;81:311-316. doi: 10.1111/j.1600-0609.2008.01112.x.10.1111/j.1600-0609.2008.01112.x18616514Search in Google Scholar

5. Frutcher O, Blich M, Jacob G. Fatal acute myocardial infarction during severe thrombocytopenic purpura. Am J Med Sci. 2002;323:279-280.10.1097/00000441-200205000-0001012018673Search in Google Scholar

6. Torbey E, Yacoub H, McCord D, Lafferty J. Two Cases and Review of the Literature: Primary Percutaneous Angiography and Antiplatelet Management in Patients with Immune Thrombocytopenic Purpura. ISRN Hematology. 2013;2013:174659. doi: 10.1155/2013/174659.10.1155/2013/174659388867924459590Search in Google Scholar

7. Russo A, Cannizzo M, Ghetti G, Branzi A. Idiopathic thrombocytopenic purpura and coronary artery disease: comparison between coronary artery bypass grafting and percutaneous coronary intervention. Interact Cardiovasc Thorac Surg. 2011;13:153-157. doi: 10.1510/icvts.2011.271296.10.1510/icvts.2011.27129621576275Search in Google Scholar

8. Fujino S, Niwa S, Fujioka K, et al. Primary Percutaneous Coronary Intervention by a Stentless Technique for Acute Myocardial Infarction with Idiopathic Thrombocytopenic Purpura: A Case Report and Review of the Literature. Intern Med. 2016;55:147-152. doi: 10.2169/internalmedicine.55.4544.10.2169/internalmedicine.55.454426781014Search in Google Scholar

9. Shen F, Nfor T, Bajwa T. Recurrent acute myocardial infarction in patients with immune thrombocytopenic purpura. J Patient Cent Res Rev. 2014;1:41-45. doi: 10.17294/2330-0698.1010.10.17294/2330-0698.1010Search in Google Scholar

10. Sakai H, Goto S, Kim JY, et al. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost. 2000;84:204-209.10.1055/s-0037-1613997Search in Google Scholar

11. Sonneveld MA, Cheng JM, Oemrawsingh RM, et al. Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Thromb Haemost. 2015;113:577-584. doi: 10.1160/TH14-07-0589.10.1160/TH14-07-058925472874Search in Google Scholar

12. Lim MY, Pruthi RK. Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: a single center experience and review of the literature. Thromb Res. 2012;130:316-322. doi: 10.1016/j.thromres.2012.02.050.10.1016/j.thromres.2012.02.05022445429Search in Google Scholar

13. Rathore S, Deleon D, Akram H, Sane D, Ball T. Percutaneous Coronary Intervention and the Management of Acute Coronary Syndromes in Patients With von Willebrand Disease. J Invasive Cardiol. 2013;25:E81-E86.Search in Google Scholar

14. Rana MA, Vutukuri NM, Acharya MM, Akkus NI. Acute coronary syndrome and coronary intervention in a patient with type 2M von Willebrand disease. Int J Cardiol. 2014;176:484-485. doi: 10.1016/j.ijcard.2014.06.066.10.1016/j.ijcard.2014.06.06625127978Search in Google Scholar

15. Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood. 2016;128:178-184. doi: 10.1182/blood-2015-12-635094.10.1182/blood-2015-12-635094494619927106121Search in Google Scholar

16. Zawilska K, Podolak-Dawidziak M. Therapeutic problems in elderly patients with hemophilia. Pol Arch Med Wewn. 2012;122:567-576.10.20452/pamw.1466Search in Google Scholar

17. Staritz P, de Moerloose P, Schutgens R, Dolan G; ADVANCE Working Group. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia. Haemophilia. 2013;19:833-840. doi: 10.1111/hae.12189.10.1111/hae.1218923710576Search in Google Scholar

18. Fefer P, Gannot S, Lubetsky A. Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome: an interventional dilemma: case series, review of the literature, and tips for management. J Thromb Thrombolysis. 2013;35:271-278. doi: 10.1007/s11239-012-0802-y.10.1007/s11239-012-0802-y22956409Search in Google Scholar

19. Minuk L, Jackson S, Iorio A. Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study). Haemophilia. 2015;21:736-741. doi: 10.1111/hae.12768.10.1111/hae.1276826222883Search in Google Scholar

20. Fransen van de Putte, Fischer K, Pulles AE, et al. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res. 2012;130:157-162. doi: 10.1016/j.thromres.2011.12.012.10.1016/j.thromres.2011.12.01222209337Search in Google Scholar

21. Fogarty PF, Mancuso ME, Kasthuri R, et al. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015;21:589-597. doi: 10.1111/hae.12652.10.1111/hae.1265225689278Search in Google Scholar

22. Provan D, Baglin T, Dokal I. Oxford Handbook of Clinical Haematology. 4th ed. Oxford University Press; 2015. p. 258-261.10.1093/med/9780199683307.001.0001Search in Google Scholar

23. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. N Engl J Med. 2004;350:114-124. doi: 10.1056/NEJMoa03557210.1056/NEJMoa03557214711910Search in Google Scholar

24. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176-2184. doi: 10.1182/blood-2013-03-460154.10.1182/blood-2013-03-46015423823316Search in Google Scholar

25. Tortorella G, Calzolari M, Tieghi A, Muià N, Piccin A, Gugliotta L. Acute coronary syndrome (ACS) in patients with essential thrombocytemia (ET). What is the best treatment. International Journal of Cardiology 2016;203:225–227. http://dx.doi.org/10.1016/j.ijcard.2015.10.043.10.1016/j.ijcard.2015.10.04326512843Search in Google Scholar

26. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372-380. doi: 10.3324/haematol.12053.10.3324/haematol.1205318268279Search in Google Scholar

27. Ziakas PD. Effect of JAK2 V617F On Thrombotic Risk In Patients With Essential Thrombocytemia: Measuring the Uncertain. Haematologica. 2008;93:1412-1414. doi: 10.3324/haematol.12970.10.3324/haematol.1297018641024Search in Google Scholar

28. Lee HS, Park LC, Lee EM, et al. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin Lymphoma Myeloma Leuk. 2012;12:70-75. doi: 10.1016/j.clml.2011.10.002.10.1016/j.clml.2011.10.00222088920Search in Google Scholar

29. Pósfai É, Marton I, Borbényi Z, Nemes A. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. Anatol J Cardiol. 2016;16:397-402. doi: 10.14744/AnatolJCardiol.2015.6125.10.14744/AnatolJCardiol.2015.6125533137027182615Search in Google Scholar

30. Zhang Y, Zheng K, Zheng M, Liu Q, Meng L. The positive therapeutic effect in a patient of Evans syndrome combined with acute myocardial infarction. Int J Clin Exp Med. 2015;8:9590-9594.Search in Google Scholar

31. Kizilirmak F, Demir GG, Cakal B, Bekoz HS, Olgun FE. Evans syndrome with non-ST segment elevation myocardial infarction complicated by hemopericardium. Indian Heart J. 2016;68(Suppl2):S280-S283. doi: 10.1016/j.ihj.2015.11.041.10.1016/j.ihj.2015.11.041506745427751316Search in Google Scholar

32. Zöller B, Li X, Sundquist J, Sundquist K. Risk of Subsequent Coronary Heart Disease in Patients Hospitalized for Immune-Mediated Diseases: A Nationwide Follow-Up Study from Sweden. PLoS One. 2012;7:e33442. doi: 10.1371/journal.pone.0033442.10.1371/journal.pone.0033442330639722438933Search in Google Scholar

33. Assanasen C, Quinton RA, Buchanan GR. Acute myocardial infarction in sickle cell anemia. J Pediatr Hematol Oncol. 2003;25:978-981.10.1097/00043426-200312000-0001514663284Search in Google Scholar

34. Gladwin MT, Sachdev V. Cardiovascular Abnormalities in Sickle Cell Disease. J Am Coll Cardiol. 2012;59:1123-1133. doi: 10.1016/j.jacc.2011.10.900.10.1016/j.jacc.2011.10.900388118822440212Search in Google Scholar

35. Bhaskar V, Joshi C. Effect of Sickle Cell Disease on Cardiovascular System: A 4.5 Years Autopsy Study Conducted in a Tertiary Care Center of Central India. International Journal of Scientific Study 2016;4:188-192. doi: 10.17354/ijss/2016/404.Search in Google Scholar

36. van Bijnen STA, van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria J Thromb Haemost. 2012;10:1-10. doi: 10.1111/j.1538-7836.2011.04562.x.10.1111/j.1538-7836.2011.04562.x22077430Search in Google Scholar

37. Muñoz-Linares C, Ojeda E, Forés R, et al. Paroxysmal nocturnal hemoglobinuria: a single Spanish center’s experience over the last 40 year. Eur J Haematol. 2014;93:309-319. doi: 10.1111/ejh.12346.10.1111/ejh.12346423287824758317Search in Google Scholar

38. Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007;5:642-645. doi: 10.1111/j.1538-7836.2007.02379.x.10.1111/j.1538-7836.2007.02379.x17319910Search in Google Scholar

39. Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016;103:649-654. doi: 10.1007/s12185-016-1995-1.10.1007/s12185-016-1995-127059871Search in Google Scholar

40. Shin HS, Kang TS. A Case of Late Stent Thrombosis Following Platelet Transfusion in a Patient With Aplastic Anemia. Korean Circ J. 2012;42:54–57. doi: 10.4070/kcj.2012.42.1.54.10.4070/kcj.2012.42.1.54328375622363385Search in Google Scholar

41. Altwegg SC, Altwegg LA, Maier W. Intracoronary thrombus with tissue factor expression heralding acute promyelocytic leukaemia. Eur Heart J. 2007;28:2731. doi: 10.1093/eurheartj/ehm216.10.1093/eurheartj/ehm21617561495Search in Google Scholar

42. Sargsyan Z, Higgins C, Alexandrescu S, Ott DA, Jain SK. Acute Promyelocytic Leukemia as a Cause of Intracoronary Drug-Eluting-Stent Thrombosis. Tex Heart Inst J. 2012;39:416-419.Search in Google Scholar

43. Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016;128:488-496. doi: 10.1182/blood-2016-01-635060.10.1182/blood-2016-01-635060552453227235136Search in Google Scholar

44. Cahill TJ, Chowdhury O, Myerson SG, et al. Myocardial Infarction With Intracardiac Thrombosis as the Presentation of Acute Promyelocytic Leukemia. Circulation. 2011;123:e370-e372. doi: 10.1161/CIRCULATIONAHA.110.986208.10.1161/CIRCULATIONAHA.110.98620821403118Search in Google Scholar

45. Muñiz AE. Myocardial infarction and stroke as the presenting symptoms of acute myeloid leukemia. J Emerg Med. 2012;42:651-654. doi: 10.1016/j.jemermed.2009.04.061.10.1016/j.jemermed.2009.04.06119500934Search in Google Scholar

46. Colović N, Bogdanović A, Virijević M, Vidović A, Tomin D. Acute Myocardial Infarction during Induction Chemotherapy for Acute MLL t(4;11) Leukemia with Lineage Switch and Extreme Leukocytosis. Srp Arh Celok Lek. 2015;143:734-738.10.2298/SARH1512734C26946771Search in Google Scholar

47. Cohen Y, Amir G, Da’as N, Gillis S, Rund D, Polliack A. Acute Myocardial Infarction as the Presenting Symptom of Acute Myeloblastic Leukemia With Extreme Hyperleukocytosis. Am J Hematol. 2002;71:47-49. doi: 10.1002/ajh.10155.10.1002/ajh.1015512221675Search in Google Scholar

48. Oshima T, Ikutomi M, Shinohara H, et al. Acute Myocardial Infarction Caused by Thrombotic Microangiopathy Complicated With Myelodysplastic Syndrome. International Heart Journal. 2016;5:634-636. http://doi.org/10.1536/ihj.16-100.10.1536/ihj.16-10027628419Search in Google Scholar

49. Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. American Journal of Blood Research. 2011;1:160-166.Search in Google Scholar

50. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte Count and Coronary Heart Disease. Implications for Risk Assessment. J Am Coll Cardiol. 2004;44:1945-1956. doi: 10.1016/j.jacc.2004.07.056.10.1016/j.jacc.2004.07.05615542275Search in Google Scholar

51. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol. 2005;25:658-670. doi: 10.1161/01.ATV.0000156877.94472.a5.10.1161/01.ATV.0000156877.94472.a515662026Search in Google Scholar

52. Assiri AH, Lambda M, Veinot JP. Chronic lymphocytic leukemia involving the coronary arteries with accompanying acute myocardial infarction. Cardiovasc Pathol. 2005;14:324-326. doi: 10.1016/j.carpath.2005.07.006.10.1016/j.carpath.2005.07.00616286042Search in Google Scholar

53. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study. J Natl Cancer Inst. 2007;99:206-214. doi: 10.1093/jnci/djk029.10.1093/jnci/djk02917284715Search in Google Scholar

54. Galper SL, Yu JB, Mauch PM, et. al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117:412-418. doi: 10.1182/blood-2010-06-291328.10.1182/blood-2010-06-29132820858859Search in Google Scholar

55. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-1886. doi: 10.1182/blood-2006-07-034405.10.1182/blood-2006-07-03440517119114Search in Google Scholar

56. Roy A, Khanna N, Senguttuvan NB. Rituximab-vincristine chemotherapy-induced acute anterior wall myocardial infarction with cardiogenic shock. Tex Heart Inst J. 2014;41:80-82. doi: 10.14503/THIJ-12-2853.10.14503/THIJ-12-2853396749024512409Search in Google Scholar

57. Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15:187-190.Search in Google Scholar

58. Gogia A, Khurana S, Paramanik R. Acute Myocardial Infarction after First Dose of Rituximab Infusion. Turkish Journal of Hematology. 2014;31:95-96. doi:10.4274/Tjh.2013.0247.10.4274/Tjh.2013.0247399662724764738Search in Google Scholar

59. Rathi S, Shakir F, Sech C, Lazzara R. Non-Hodgkin Lymphoma Causing Acute Myocardial Infarction and Tachyarrhythmia Am J Cardiol. 2009;104:450-452. doi: 10.1016/j.amjcard.2009.03.065.10.1016/j.amjcard.2009.03.06519616683Search in Google Scholar

60. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991-4998. doi: 10.1182/blood-2009-11-252072.10.1182/blood-2009-11-252072289015020299513Search in Google Scholar

61. Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood. 2010;116:22-26. doi: 10.1182/blood-2009-12-257519.10.1182/blood-2009-12-25751920339094Search in Google Scholar

62. Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:437-444. doi: 10.1182/asheducation-2010.1.437.10.1182/asheducation-2010.1.43721239832Search in Google Scholar

63. Weijuan L, Frank C, Daniel L, et al. Cardiovascular Complications of Novel Multiple Myeloma Treatments. Circulation. 2016;133:908-912. https://doi.org/10.1161/CIRCULATIONAHA.115.018351.10.1161/CIRCULATIONAHA.115.01835126927008Search in Google Scholar

64. Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol. 2010;91:903-906. doi: 10.1007/s12185-010-0586-9.10.1007/s12185-010-0586-920458563Search in Google Scholar